Company
Headquarters: Shijiazhuang, China
Employees: 10,909
CN¥9.57 Billion
CNY as of Jan. 1, 2026
US$1.36 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
North China Pharmaceutical Company Ltd. operates as a chemical pharmaceutical company in China. It primarily offers anti-infective drugs, comprising APIs, and intermediates and their preparations; biotechnology drugs; cardiovascular and immunomodulators; vitamins health consumer products; and bio-agricultural and veterinary drugs. North China Pharmaceutical Company Ltd. was founded in 1953 and is based in Shijiazhuang, China.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | CN¥9.79 B |
| EBITDA | CN¥846.2 M |
| Gross Profit TTM | CN¥3.04 B |
| Profit Margin | 1.87% |
| Operating Margin | 5.25% |
| Quarterly Revenue Growth | -5.10% |
North China Pharmaceutical Company Ltd has the following listings and related stock indices.
Stock: SSE: 600812